論文・技術情報追加のお知らせ

1. Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

小児における抗てんかん薬によるDRESS発症リスクのFAERS解析。

対象DB：FAERS

2. Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin.

ロスバスタチンとBCRP阻害薬の併用による横紋筋融解症リスク。

対象DB：FAERS

3. Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.

尿路上皮がんへのエンフォルツマブ等併用療法のリアルワールド解析。

対象DB：FAERS,VigiBase

4. Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database.

イピリムマブとニボルマブの安全シグナルと関連因子をFAERSで評価。

対象DB：FAERS

5. Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases.

キャンディン系抗真菌薬3種の安全プロファイルを複数DBで比較。

対象DB：FAERS

6. [Analysis of cardiovascular adverse events associated with 8 immune checkpoint inhibitors based on the FAERS database].

8種の免疫チェックポイント阻害薬による心血管副作用をFAERSで解析。

対象DB：FAERS

7. Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 - 2024.

小児における遺伝子組換え成長ホルモン療法の市販後安全性評価。

対象DB：FAERS

8. Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system.

非小細胞肺がんへの免疫二剤併用による重篤な腎・膵毒性の解析。

対象DB：FAERS

9. Differences in Reported Anaphylaxis Associated With Common Nonsteroidal Anti-inflammatory Drugs: A Pharmacovigilance Study.

各種NSAIDsにおけるアナフィラキシー報告の差異を不均衡解析。

対象DB：FAERS

10. Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Children in the Vaccine Adverse Event Reporting System.

小児における20価肺炎球菌結合型ワクチンの安全性をVAERSで評価。

対象DB：FAERS,VAERS

11. Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database.

妊婦におけるノイラミニダーゼ阻害薬の副作用シグナルをFAERSで解析。

対象DB：FAERS

12. Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.

CAR-T療法後の免疫作動細胞関連血液毒性を大規模データベースで評価。

対象DB：FAERS

13. Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

新世代抗てんかん薬によるSJS/TENリスクのFAERS解析。

対象DB：FAERS,JADER

14. Adverse Event Profiling and Comparative Analysis of HER2-targeting Antibody-drug Conjugates Using Pharmacovigilance Databases.

HER2標的ADC製剤の副作用プロファイルと不均衡比較解析。

対象DB：FAERS,JADER

15. Safety evaluation of CD3xCD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

CD3xCD20二特異性抗体の安全性をFAERSデータに基づき評価。

対象DB：FAERS

16. Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis.

IBDにおけるウパダシチニブの安全性を複数DB統合アプローチで評価。

対象DB：FAERS

17. Drug combination choices of 5alpha-reductase inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database.

前立腺肥大症患者での5α還元酵素阻害薬とα遮断薬の併用パターン。

対象DB：FAERS

18. Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.

米国VAERSデータからみるRSVワクチンの副作用と接種ミス。

対象DB：FAERS,VAERS

19. Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study.

薬剤性急性呼吸窮迫症候群（ARDS）のリスクシグナルFAERS解析。

対象DB：FAERS

20. Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database.

ロフルミラスト誘発性精神系イベントのFAERSリアルワールド解析。

対象DB：FAERS

21. Avacopan-Associated Hepatotoxicity: Clinical Signal, Liver Injury Patterns, and Plausible Mechanisms.

アバコパン関連肝毒性の臨床シグナル、損傷パターンと機序。

対象DB：FAERS

22. The real-world safety evaluation of the selective NaV1.8 inhibitor suzetrigine: disproportionality analysis and flexible empirical bayes signals from FAERS with external triangulation.

選択的NaV1.8阻害薬スゼトリジンのリアルワールド安全性評価。

対象DB：FAERS,VigiBase

23. Adverse Event Profile of Apremilast: Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS).

アプレミラストの副作用プロファイルをFAERSデータに基づき解析。

対象DB：FAERS

24. Application Site Adverse Events of Topical Nonsteroidal Immunomodulators: A Post-Marketing Analysis of the FDA Adverse Event Reporting System.

外用非ステロイド性免疫調節薬の適用部位副作用の市販後解析。

対象DB：FAERS

25. Cognitive dysfunction associated with endocrine therapy and CDK4/6 inhibitors in breast cancer: A real-world analysis of the FDA Adverse Event Reporting System (FAERS) database.

乳がん治療薬（内分泌・CDK4/6阻害薬）による認知機能障害。

対象DB：FAERS

26. Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate.

JADERデータマイニングと動物実験による薬剤リスク評価。

対象DB：JADER

27. Temporal Trends in Antineoplastic Agent-associated Interstitial Lung Disease Involving Immune Checkpoint Inhibitors in the JADER Database.

日本における免疫チェックポイント阻害薬関連間質性肺疾患の動向。

対象DB：JADER

28. The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

不均衡解析における弁労士の報告バイアスの双方向性に関する検討。

対象DB：VigiBase

29. Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

スウェーデンにおけるメタミゾール誘発性無顆粒球症の動向と規制。

対象DB：VigiBase

30. Prevalence and clinical characteristics of Terson syndrome among survivors of aneurysmal subarachnoid hemorrhage: a nationwide study in Japan.

日本における動脈瘤性くも膜下出血生存者のテルソン症候群の特徴。

対象DB：DPC

31. Risk factors and early onset predictors of contralateral hip fractures following initial treatment of the other hip fracture.

初回股関節骨折治療後の対側股関節骨折リスク因子と早期予測因子。

対象DB：DPC,MDV

32. Nationwide trends in outcomes and resource utilization in surgically treated acute type A aortic dissection with coronary malperfusion.

急性A型大動脈解離手術における転帰と医療資源利用の全国動向。

対象DB：DPC

33. Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

日本における水痘帯状疱疹ウイルス髄膜炎の発症率増加傾向（11-22年）。

対象DB：DPC

34. Differential impact of institutional procedural volume on outcomes of transcatheter and surgical strategies for concomitant aortic stenosis and coronary artery disease: a nationwide registry study.

経カテーテルおよび手術戦略の施設症例数が治療転帰に与える影響。

対象DB：DPC

35. Nationwide trends in outpatient rates for ophthalmic surgeries in Japan before and after the COVID-19 pandemic: an analysis of the NDB open data.

コロナ禍前後における日本での眼科手術の院外通院率の全国動向。

対象DB：NDB

36. Life-Course Patterns of Medical and Dental Care in Patients with Cleft Lip and/or Palate: A Nationwide Claims-Based Study.

口唇口蓋裂患者における医療・歯科ケアのライフコースパターン。

対象DB：NDB

37. Age and Regional Trends in Groin Hernia Surgery in Japan: An Analysis of Laparoscopic Repair, Outpatient Surgery, and Manual Reduction Using National Database Open Data.

日本における鼠径ヘルニア手術の年齢・地域動向と腹腔鏡修復の普及。

対象DB：NDB

38. Rising Pancreatic Cancer Incidence in Young Japanese Women and Increasing Distal Pancreatectomy in Older Adults: A Nationwide Claims-Based Analysis From 2016 to 2023.

日本の若年女性における膵臓がん罹患率増加と高齢者の尾側膵切除。

対象DB：NDB

39. Politics in psychiatry and psychotherapis in Japan with personal reflection; Is cognitive behavior therapy non-political?

日本の精神医学・心理療法における政治性とCBTに関する考察。

対象DB：NDB

40. Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England.

免疫不全成人でのSARS-CoV-2追加接種と入院・死亡リスクの関連。

対象DB：CPRD

41. Temporal associations between incident physical health problems/sensory impairments and challenging behaviours in people with intellectual disabilities: a population-based longitudinal cohort study of primary care in England.

知的障害者での身体疾患・感覚障害の発生と挑戦的行動の経時的関連。

対象DB：CPRD

42. Patient Perceptions of Artificial Intelligence-Supported Shared Decision-Making in UK Primary Care for Multiple Long-Term Conditions: Qualitative Study.

英国プライマリケアでの複数慢性疾患患者によるAI意思決定支援の認識。

対象DB：CPRD

43. Learning disability register enrolment in young people in England: Cohort Study, 2015-2023.

イングランドの若年者における学習障害レジスター登録動向のコホート。

対象DB：CPRD

44. Assessment of the healthcare burden of dengue disease in England: a retrospective analysis (2010-2023).

英国におけるデング熱の医療負担に関する後方視的解析（10-23年）。

対象DB：CPRD

45. Methods for incorporating test result information within the high-dimensional propensity score framework: application in UK electronic health record data.

高次元傾向スコア枠組みに検査結果情報を取り入れる手法の応用。

対象DB：CPRD

46. Leveraging primary care data to understand military veteran health in England: feasibility study and matched-control comparison of recorded conditions.

英国退役軍人の健康状態把握におけるプライマリケアデータの活用。

対象DB：CPRD

47. Mortality rates in children, young people, and young adults with JIA: an observational study using the Clinical Practice Research Datalink (CPRD).

若年性特発性関節炎患者の死亡率に関するプライマリケアコホート。

対象DB：CPRD

48. Estimating Adverse Events Associated With Herbal Medicines Using Pharmacovigilance Databases: Systematic Review and Meta-Analysis.

副作用DBを用いた生薬関連副作用の推定に関する系統的レビュー。

対象DB：CVAR

49. Methotrexate and folic acid supplementation in rheumatoid arthritis: A Japanese claims database and 538,985 patients from April 2015 to November 2020.

関節リウマチ患者でのメトトレキサートと葉酸補給に関する国内調査。

対象DB：DeSC